LONDON, May 26, 2016 /PRNewswire/ -- This report analyzes
the worldwide markets for Cardiac Biomarkers in US$ Thousand by the
following Testing Locations: Laboratory Testing, and Point of Care
Testing. The Global, US and European markets are further analyzed
by the following Test Types: Cardiac Troponin, BNP and NT-proBNP,
and Others. The report provides separate comprehensive analytics
for the US, Canada, Japan, Europe, Asia-Pacific, Latin
America, and Rest of World. Annual estimates and forecasts
are provided for the period 2015 through 2022. Also, a six-year
historic analysis is provided for these markets. Market data and
analytics are derived from primary and secondary research. Company
profiles are primarily based on public domain information including
company URLs. The report profiles 44 companies including many key
and niche players such as -
Abbott Diagnostics, Inc.
Alere, Inc.
Beckman Coulter, Inc.
BG Medicine, Inc.
biomérieux SA
Download the full report:
https://www.reportbuyer.com/product/3846692/
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers.............. I-2 Data Interpretation & Reporting
Level I-2 Quantitative Techniques & Analytics I-2 Product
Definition and Scope of Study I-3 Cardiac Biomarkers..............
I-3 Testing Location..............I-3 Laboratory
Testing..............I-4 Point of Care Testing..............I-4
Types of Cardiac Biomarkers..............I-4 Cardiac
Troponin.............. I-5 Natriuretic Peptides..............I-5
BNP (B-type Natriuretic Peptide) I-5 NT-proBNP (N-terminal proBNP)
I-5 Others.............. I-5 Creatine Kinase-MB (CK-MB) I-5
Myoglobin.............. I-5
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW.............. II-1 Curtain
Raiser.............. II-1 Major Cardiac Markers and their
Properties II-2 Current and Future Scenario..............II-2 North
America Corners Biggest Slice, Asia-Pacific to Dictate Market
Momentum.............. II-2 Laboratory Testing Remains Gold
Standard, POC Testing Rapidly Gains Traction.............. II-3
Analysis by Type of Cardiac Biomarker Assay/Test II-5 Emerging
Markets, New Product Introductions Hold Key to Reviving Saturated
Cardiac Troponin Assays Market II-6 Competitive
Landscape..............II-7 Intense Competition among Players in
the Cardiac Diagnostics Market.............. II-7 Leading Vendors
Focus on Curtailing Turnaround Time of POC Cardiac Testing
Kits..............II-7 Cardiac Markers Point-Of-Care Testing (POC)
Cardiac Testing Segment: Major Players and their Operating Brands
II-8
2. MARKET GROWTH DRIVERS, TRENDS & ISSUES II-9 The Grim Reality
of Mounting Economic and Social Burden of Cardiovascular
Disease..............II-9 Table 1: Prevalence of Heart Failure in
Select Countries (includes corresponding Graph/Chart) II-9
Population Explosion, Ballooning Geriatric Populace, Longer Life
Expectancy Contributing to Rising Tide of CVDs II-10 Table 2:
Global Population Estimates (in Billion): 2000-2050P (includes
corresponding Graph/Chart) II-10
Table 3: Aging (65+) Demographics as a Percentage of Total
Population for Major Countries: 2000, 2011, and 2020 (includes
corresponding Graph/Chart) II-11
Table 4: Global Aging Population (in Thousands) by Age Group: 1975,
2000, 2025, and 2050 (includes corresponding
Graph/Chart).............. II-11
Table 5: Global Population Statistics for the 65+ Age Group (Male
& Female) for Major Countries/Regions: 2013 (includes
corresponding Graph/Chart)..............II-12
Table 6: Global Life Expectancy at Age 60 and 80 Years: 2010-2015;
2020-2025; and 2045-2050 (includes corresponding
Graph/Chart).............. II-13
Table 7: Life Expectancy for Select Countries in Number of Years:
2015E (includes corresponding Graph/Chart) II-14 Cardiac Biomarkers
Hold the Key to Timely, Accurate Diagnosis &
Prognosis.............. II-14 Commercialization of Novel Biomarkers
to Drive Market Growth II-15 Personalized Medicine, Companion
Diagnostics Open Up Opportunities for Cardiac Biomarker Developers
II-16 Cardiac Biomarkers - a Powerful Tool for Patient Triaging
II-17 Cardiac Biomarkers Market Transitions from Mono-Marker to
Multi-Marker Assays..............II-17 Government Support
Instrumental for Boosting Market Momentum II-18 Secretoneurin
Biomarker - a Potential Game Changer for Diagnosis of Cardiac
Arrhythmias II-18 High-Performance Techniques Drive Biomarker
Discovery in Cardiology.............. II-19 Biomarkers for Acute
Coronary Syndromes (ACS): A Leading Segment II-20 Biomarkers - A
Promising Diagnostic Tool for ACS II-21 Biomarker Discovery for ACS
to Undergo Significant Changes II-22 Cardiac Biomarker Play
Critical Role in Stroke Diagnosis II-22 Cardiac Biomarkers to Find
a Place in Neonatal Diagnosis and Treatment.............. II-23
Specificity, Sensitivity, Side Effects, Cost Concerns Hinder Market
Growth.............. II-23
3. PRODUCT OVERVIEW.............. II-24 Cardiac
Biomarkers..............II-24 Necessity of a Cardiac Marker Assay
Test II-24 Cardiac Markers and Myocardial Infarction (MI) II-25
Chain Reaction after an Event of MI II-25 Action Plan after an
Event of MI II-26 Protocol for Conducting AMI Markers Tests II-26
Myocardial Infarction Cardiac Biomarkers - Benefits and
Limitations.............. II-26 Cardiac Markers and Congestive
Heart Failure (Chf) II-27 Key Facts.............. II-27 Types of
Cardiac Biomarkers..............II-28 Major Cardiac Markers and
their Properties II-28 Creatine Kinase - The Gold Standard Losing
Sheen II-28 Isomers.............. II-28 Kinetics..............
II-29 Purpose of Test and When to Order II-29
Evaluation.............. II-29 Points to
remember..............II-29 Cardiac Troponin.............. II-29
Troponin Tissue-Specific Subtypes II-30 Other
Diseases.............. II-30 Uses of Troponin
Tests..............II-30 New Advanced High-sensitivity (Hs) Cardiac
Troponin Tests II-30 Myoglobin.............. II-31 Purpose of Test
and When to Order II-31 Testing and Evaluation..............II-31
Points of Caution.............. II-32 Natriuretic
Peptides..............II-32 BNP (B-type Natriuretic Peptide) II-32
NT-proBNP (N-terminal proBNP)..............II-33 Purpose of Tests
and When to Order II-33 Testing and Evaluation..............II-33
Points to Remember..............II-33 Introduction of BNP Test and
the Changing Market Scenario in the Segment: A
Review..............II-33 Choosing the Right BNP and NT proBNP
Assay Kit in the Market II-34 Evolution of BNP and NT proBNP Market
II-34 NT-proBNP is superior to BNP in Predicting Mortality in Heart
Failure Patients, with Reduced Kidney Function II-35 Other
Important Cardiac Biomarkers II-35 Homocysteine.............. II-35
C-Reactive Protein..............II-36 Plasminogen Activator
Inhibitor-1 II-36 D-Dimer.............. II-36 Thrombus Precursor
Protein..............II-37 Galectin-3 Biomarker..............II-37
Galectin-3: An Overview of Clinical Studies II-37 Galectin-3:
Overview of Clinical Studies in Cardiovascular Disease
Diagnosis..............II-37 Potential Future Cardiac Biomarkers
II-38 Location of Cardiac Biomarker Testing II-39 Laboratory
Cardiac Testing..............II-39 Point-of-Care Cardiac Testing
II-40
4. PRODUCT INTRODUCTIONS..............II-41 Singulex Secures US
Patent for Cardiac Troponin I and T Biomarkers for Detecting CVDs
II-41 Singulex Wins European Patent for Cardiac Troponin I and T
Biomarkers for Detecting Cardiac Damage II-41 Critical Diagnostics
Receives China FDA Clearance for Clinical Use of Presage ST2
Assay..............II-41 Critical Diagnostics Secures CE Mark for
Aspect-PLUS ST2 Test II-41 Roche Diagnostics Introduces Improved
Cardiac POC Troponin T test for cobas h 232
System..............II-41 BG Medicine Receives US Patent for
Galectin-3 and Cardiac Resynchronization Therapy..............II-41
Critical Diagnostics Unveils Aspect-LF ST2 Test II-42 Olink
Bioscience Unveils Proseek Multiplex CVD I96x96 Protein Biomarker
Panel.............. II-42 BG Medicine Gains AHA and ACCF
Recognition for Galectin-3 Testing II-42
5. RECENT INDUSTRY ACTIVITY..............II-43 Eurofins Scientific
Completes Takeover of Boston Heart Diagnostics
Corp...............II-43 Lee Biosolutions Steps Up Investment for
Development of High Value Cardiac Markers..............II-43 MaRS
Innovation Enters into Collaboration with Johnson & Johnson
Innovation and Janssen..............II-43 ACS Biomarker BV
Establishes Mirnext BV II-43 Critical Diagnostics Releases Results
of Study on Cardiac Biomarker ST2.............. II-43
6. FOCUS ON SELECT PLAYERS..............II-44 Abbott Diagnostics,
Inc. (USA) II-44 Alere, Inc.
(USA).............. II-44
Beckman Coulter, Inc. (USA)..............II-45 BG Medicine, Inc.
(USA)..............II-45
biomérieux SA (France)..............II-46 Boditech Med Inc.
(South Korea)..............II-46
Labsystems Diagnostics OY (Finland) II-47 LifeSign LLC (USA)..............II-47 LSI Medience
Corporation (Japan) II-47
Ortho-Clinical Diagnostics, Inc. (USA) II-48 Randox Laboratories Ltd.
(UK)..............II-48 Response Biomedical Corp. (Canada) II-49 Roche Diagnostics Corp.
(Switzerland) II-49 Siemens
Healthcare Diagnostics, Inc. (USA)
II-50 Singulex, Inc. (USA)..............II-51
7. GLOBAL MARKET PERSPECTIVE..............II-52 Cardiac Biomarkers
Testing By Geographic Region II-52 Table 8: World Recent Past,
Current and Future Analysis for Cardiac Biomarkers by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific, Latin
America, and Rest of World Markets Independently Analyzed
with Annual Revenue Figures in US$ Thousand for Years 2015 through
2022 (includes corresponding Graph/Chart)..............II-52
Table 9: World Historic Review Analysis for Cardiac Biomarkers by
Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific, Latin
America, and Rest of World Markets Independently Analyzed
with Annual Revenue Figures in US$ Thousand for Years 2009 through
2014 (includes corresponding Graph/Chart).............. II-53
Table 10: World 14-Year Perspective for Cardiac Biomarkers by
Geographic Region - Percentage Breakdown of Dollar Revenues for US,
Canada, Japan, Europe, Asia-Pacific, Latin
America, and Rest of World Markets for Years 2009, 2016, and
2022 (includes corresponding Graph/Chart) II-54 Cardiac Biomarkers
Testing By Location of Testing II-55 Table 11: World Recent Past,
Current and Future Analysis for Cardiac Biomarkers in Laboratory
Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin
America, and Rest of World Markets Independently Analyzed
with Annual Revenue Figures in US$ Thousand for Years 2015 through
2022 (includes corresponding Graph/Chart) II-55
Table 12: World Historic Review Analysis for Cardiac Biomarkers in
Laboratory Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin
America, and Rest of World Markets Independently Analyzed
with Annual Revenue Figures in US$ Thousand for Years 2009 through
2014 (includes corresponding Graph/Chart)..............II-56
Table 13: World 14-Year Perspective for Cardiac Biomarkers in
Laboratory Testing by Geographic Region - Percentage Breakdown of
Dollar Revenues for US, Canada,
Japan, Europe, Asia-Pacific, Latin
America, and Rest of World Markets for Years 2009, 2016, and
2022 (includes corresponding Graph/Chart).............. II-57
Table 14: World Recent Past, Current and Future Analysis for
Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific, Latin
America, and Rest of World Markets Independently Analyzed
with Annual Revenue Figures in US$ Thousand for Years 2015 through
2022 (includes corresponding Graph/Chart) II-58
Table 15: World Historic Review Analysis for Cardiac Biomarkers in
Point-of-Care (POC) Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin
America, and Rest of World Markets Independently Analyzed
with Annual Revenue Figures in US$ Thousand for Years 2009 through
2014 (includes corresponding Graph/Chart) II-59
Table 16: World 14-Year Perspective for Cardiac Biomarkers in
Point-of-Care (POC) Testing by Geographic Region - Percentage
Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific, Latin
America, and Rest of World Markets for Years 2009, 2016, and
2022 (includes corresponding Graph/Chart).............. II-60
Cardiac Biomarkers Market by Assay Test Type II-61 Table 17: World
Recent Past, Current and Future Analysis for Cardiac Biomarkers by
Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others
Markets Independently Analyzed with Annual Revenue Figures in US$
Thousand for Years 2015 through 2022 (includes corresponding
Graph/Chart) II-61
Table 18: World Historic Review Analysis for Cardiac Biomarkers by
Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others
Markets Independently Analyzed with Annual Revenue Figures in US$
Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart)..............II-62
Table 19: World 14-Year Perspective for Cardiac Biomarkers by Test
Type - Percentage Breakdown of Dollar Revenues for Cardiac
Troponin, BNP & NT-proBNP, and Others Markets for Years 2009,
2016, and 2022 (includes corresponding Graph/Chart)..............
II-63
III. MARKET
1. THE UNITED STATES..............
III-1 A.Market Analysis.............. III-1 Current and Future
Analysis..............III-1 Statistics for Cardiovascular Diseases
and Stroke, and Related Risk Factors and Costs in the US III-1
Table 20: Prevalence of Cardiovascular Disease in US Adult
Population by Gender and Age (2009-2012): Prevalence Percentage of
CVDs for Males and Females of Age Groups - 20-39 Years, 40-59
Years, 60-79 Years, and 80 Years & Above (includes
corresponding Graph/Chart) III-2
Table 21: Prevalence of Stroke in US Adult Population by Gender and
Age (2009-2012): Prevalence Percentage of CVDs for Males and
Females of Age Groups - 20-39 Years, 40-59 Years, 60-79 Years, and
80 Years and Above (includes corresponding
Graph/Chart)..............III-2
Table 22: Prevalence of High Blood Pressure in US Adult Population
by Gender and Age (2009-2012): Prevalence Percentage of CVDs for
Males and Females of Age Groups - 20-34 Years, 35-44 Years, 45-54
Years, 65-74 Years, and 75 Years & Above (includes
corresponding Graph/Chart) III-3
Table 23: Prevalence of Diabetes and Obesity in US Adult Population
by Gender (2009-2012): Prevalence Percentage of Physician Diagnosed
Diabetes, Undiagnosed Diabetes, and Obesity for Males and Females
of Age 20 Years & Above (includes corresponding Graph/Chart)
III-3
Table 24: US Total Annual Average Expenditure for Cardiovascular
Diseases by Type of CVD (2015): Percentage Breakdown of Expenditure
for Heart Disease, Hypertension, Stroke and Other CVDs (includes
corresponding Graph/Chart) III-4 Product Introductions &
Approvals III-4 Strategic Corporate Developments III-5 Select Key
Players..............III-5 B.Market Analytics..............III-10
Cardiac Biomarkers Testing By Location of Testing III-10 Table 25:
The US Recent Past, Current and Future Analysis for Cardiac
Biomarkers by Location of Testing - Laboratory Testing &
Point-of-Care Testing Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for Years 2015 through 2022
(includes corresponding Graph/Chart).............. III-10
Table 26: The US Historic Review Analysis for Cardiac Biomarkers by
Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-11
Table 27: The US 14-Year Perspective for Cardiac Biomarkers by
Location of Testing - Percentage Breakdown of Dollar Revenues for
Laboratory Testing & Point-of-Care Testing Markets for Years
2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-12 Cardiac Biomarkers Market by Assay
Test Type III-13 Table 28: The US Recent Past, Current and Future
Analysis for Cardiac Biomarkers by Test Type - Cardiac Troponin,
BNP & NT-proBNP, and Others Markets Independently Analyzed with
Annual Revenue Figures in US$ Thousand for Years 2015 through 2022
(includes corresponding Graph/Chart) III-13
Table 29: The US Historic Review Analysis for Cardiac Biomarkers by
Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others
Markets Independently Analyzed with Annual Revenue Figures in US$
Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-14
Table 30: The US 14-Year Perspective for Cardiac Biomarkers by Test
Type - Percentage Breakdown of Dollar Revenues for Cardiac
Troponin, BNP & NT-proBNP, and Others Markets for Years 2009,
2016, and 2022 (includes corresponding Graph/Chart)..............
III-15
2. CANADA.............. III-16
A.Market Analysis.............. III-16 Current and Future
Analysis..............III-16 Strategic Corporate Development III-16
Select Key Player.............. III-16 B.Market
Analytics..............III-17 Table 31: Canadian Recent Past,
Current and Future Analysis for Cardiac Biomarkers by Location of
Testing - Laboratory Testing & Point-of-Care Testing Markets
Independently Analyzed with Annual Revenue Figures in US$ Thousand
for Years 2015 through 2022 (includes corresponding Graph/Chart)
III-17
Table 32: Canadian Historic Review Analysis for Cardiac Biomarkers
by Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-18
Table 33: Canadian 14-Year Perspective for Cardiac Biomarkers by
Location of Testing - Percentage Breakdown of Dollar Revenues for
Laboratory Testing & Point-of-Care Testing Markets for Years
2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-19
3. JAPAN.............. III-20
A.Market Analysis.............. III-20 Current and Future
Analysis..............III-20 LSI Medience Corporation - A Key
Japanese Player III-20 B.Market Analytics..............III-21 Table
34: Japanese Recent Past, Current and Future Analysis for Cardiac
Biomarkers by Location of Testing - Laboratory Testing &
Point-of-Care Testing Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for Years 2015 through 2022
(includes corresponding Graph/Chart) III-21
Table 35: Japanese Historic Review Analysis for Cardiac Biomarkers
by Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-22
Table 36: Japanese 14-Year Perspective for Cardiac Biomarkers by
Location of Testing - Percentage Breakdown of Dollar Revenues for
Laboratory Testing & Point-of-Care Testing Markets for Years
2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-23
4. EUROPE.............. III-24
A.Market Analysis.............. III-24 Current and Future
Analysis..............III-24 Growing Prevalence of Cardiovascular
Disease Propels Growth of European Cardiac Biomarkers Market III-24
Cardiac Markers in Primary Care Sector III-25 B.Market
Analytics..............III-26 Table 37: European Recent Past,
Current and Future Analysis for Cardiac Biomarkers by Geographic
Region - France, Germany, Italy, UK, and Rest of Europe Markets
Independently Analyzed with Annual Revenue Figures in US$ Thousand
for Years 2015 through 2022 (includes corresponding Graph/Chart)
III-26
Table 38: European Historic Review Analysis for Cardiac Biomarkers
by Geographic Region - France,
Germany, Italy, UK, and Rest of Europe Markets
Independently Analyzed with Annual Revenue Figures in US$ Thousand
for Years 2009 through 2014 (includes corresponding Graph/Chart)
III-27
Table 39: European 14-Year Perspective for Cardiac Biomarkers by
Geographic Region - Percentage Breakdown of Dollar Revenues for
France, Germany, Italy, UK, and Rest of Europe Markets for
Years 2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-28 Cardiac Biomarkers Testing By
Location of Testing III-29 Table 40: European Recent Past, Current
and Future Analysis for Cardiac Biomarkers by Location of Testing -
Laboratory Testing & Point-of-Care Testing Markets
Independently Analyzed with Annual Revenue Figures in US$ Thousand
for Years 2015 through 2022 (includes corresponding
Graph/Chart).............. III-29
Table 41: European Historic Review Analysis for Cardiac Biomarkers
by Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-30
Table 42: European 14-Year Perspective for Cardiac Biomarkers by
Location of Testing - Percentage Breakdown of Dollar Revenues for
Laboratory Testing & Point-of-Care Testing Markets for Years
2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-31 Cardiac Biomarkers Market by Assay
Test Type III-32 Table 43: European Recent Past, Current and Future
Analysis for Cardiac Biomarkers by Test Type - Cardiac Troponin,
BNP & NT-proBNP, and Others Markets Independently Analyzed with
Annual Revenue Figures in US$ Thousand for Years 2015 through 2022
(includes corresponding Graph/Chart) III-32
Table 44: European Historic Review Analysis for Cardiac Biomarkers
by Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others
Markets Independently Analyzed with Annual Revenue Figures in US$
Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-33
Table 45: European 14-Year Perspective for Cardiac Biomarkers by
Test Type - Percentage Breakdown of Dollar Revenues for Cardiac
Troponin, BNP & NT-proBNP, and Others Markets for Years 2009,
2016, and 2022 (includes corresponding
Graph/Chart)..............III-34
4a. FRANCE.............. III-35
A.Market Analysis.............. III-35 Current and Future
Analysis..............III-35 Select Key Player.............. III-35
B.Market Analytics..............III-36 Table 46: French Recent
Past, Current and Future Analysis for Cardiac Biomarkers by
Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2015 through 2022 (includes corresponding
Graph/Chart) III-36
Table 47: French Historic Review Analysis for Cardiac Biomarkers by
Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-37
Table 48: French 14-Year Perspective for Cardiac Biomarkers by
Location of Testing - Percentage Breakdown of Dollar Revenues for
Laboratory Testing & Point-of-Care Testing Markets for Years
2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-38
4b. GERMANY.............. III-39
Market Analysis.............. III-39 Table 49: German Recent Past,
Current and Future Analysis for Cardiac Biomarkers by Location of
Testing - Laboratory Testing & Point-of-Care Testing Markets
Independently Analyzed with Annual Revenue Figures in US$ Thousand
for Years 2015 through 2022 (includes corresponding Graph/Chart)
III-39
Table 50: German Historic Review Analysis for Cardiac Biomarkers by
Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-40
Table 51: German 14-Year Perspective for Cardiac Biomarkers by
Location of Testing - Percentage Breakdown of Dollar Revenues for
Laboratory Testing & Point-of-Care Testing Markets for Years
2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-41
4c. ITALY.............. III-42
Market Analysis.............. III-42 Table 52: Italian Recent Past,
Current and Future Analysis for Cardiac Biomarkers by Location of
Testing - Laboratory Testing & Point-of-Care Testing Markets
Independently Analyzed with Annual Revenue Figures in US$ Thousand
for Years 2015 through 2022 (includes corresponding Graph/Chart)
III-42
Table 53: Italian Historic Review Analysis for Cardiac Biomarkers
by Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-43
Table 54: Italian 14-Year Perspective for Cardiac Biomarkers by
Location of Testing - Percentage Breakdown of Dollar Revenues for
Laboratory Testing & Point-of-Care Testing Markets for Years
2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-44
4d. THE UNITED KINGDOM..............III-45 A.Market
Analysis.............. III-45 Current and Future
Analysis..............III-45 Randox Laboratories Ltd. - A Key
Player III-45 B.Market Analytics..............III-46 Table 55: The
UK Recent Past, Current and Future Analysis for Cardiac Biomarkers
by Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2015 through 2022 (includes corresponding
Graph/Chart) III-46
Table 56: The UK Historic Review Analysis for Cardiac Biomarkers by
Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-47
Table 57: The UK 14-Year Perspective for Cardiac Biomarkers by
Location of Testing - Percentage Breakdown of Dollar Revenues for
Laboratory Testing & Point-of-Care Testing Markets for Years
2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-48
4e. SPAIN.............. III-49
Market Analysis.............. III-49 Table 58: Spanish Recent Past,
Current and Future Analysis for Cardiac Biomarkers by Location of
Testing - Laboratory Testing & Point-of-Care Testing Markets
Independently Analyzed with Annual Revenue Figures in US$ Thousand
for Years 2015 through 2022 (includes corresponding Graph/Chart)
III-49
Table 59: Spanish Historic Review Analysis for Cardiac Biomarkers
by Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-50
Table 60: Spanish 14-Year Perspective for Cardiac Biomarkers by
Location of Testing - Percentage Breakdown of Dollar Revenues for
Laboratory Testing & Point-of-Care Testing Markets for Years
2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-51
4f. RUSSIA.............. III-52
Market Analysis.............. III-52 Table 61: Russian Recent Past,
Current and Future Analysis for Cardiac Biomarkers by Location of
Testing - Laboratory Testing & Point-of-Care Testing Markets
Independently Analyzed with Annual Revenue Figures in US$ Thousand
for Years 2015 through 2022 (includes corresponding Graph/Chart)
III-52
Table 62: Russian Historic Review Analysis for Cardiac Biomarkers
by Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-53
Table 63: Russian 14-Year Perspective for Cardiac Biomarkers by
Location of Testing - Percentage Breakdown of Dollar Revenues for
Laboratory Testing & Point-of-Care Testing Markets for Years
2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-54
4g. REST OF EUROPE..............
III-55 A.Market Analysis.............. III-55 Current and Future
Analysis..............III-55 Product Introductions & Approvals
III-55 Strategic Corporate Development III-55 Select Key
Players..............III-56 B.Market Analytics..............III-57
Table 64: Rest of Europe Recent Past, Current and Future Analysis
for Cardiac Biomarkers by Location of Testing - Laboratory Testing
& Point-of-Care Testing Markets Independently Analyzed with
Annual Revenue Figures in US$ Thousand for Years 2015 through 2022
(includes corresponding Graph/Chart).............. III-57
Table 65: Rest of Europe Historic Review Analysis for Cardiac
Biomarkers by Location of Testing - Laboratory Testing &
Point-of-Care Testing Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for Years 2009 through 2014
(includes corresponding Graph/Chart) III-58
Table 66: Rest of Europe 14-Year
Perspective for Cardiac Biomarkers by Location of Testing -
Percentage Breakdown of Dollar Revenues for Laboratory Testing
& Point-of-Care Testing Markets for Years 2009, 2016, and 2022
(includes corresponding Graph/Chart)..............III-59
5. ASIA-PACIFIC..............
III-60 Market Analysis.............. III-60 Table 67: Asia-Pacific
Recent Past, Current and Future Analysis for Cardiac Biomarkers by
Geographic Region - China,
India, and Rest of Asia-Pacific
Markets Independently Analyzed with Annual Revenue Figures in US$
Thousand for Years 2015 through 2022 (includes corresponding
Graph/Chart) III-61
Table 68: Asia-Pacific Historic Review Analysis for Cardiac
Biomarkers by Geographic Region - China, India,
and Rest of Asia-Pacific Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for Years 2009 through 2014
(includes corresponding Graph/Chart) III-62
Table 69: Asia-Pacific 14-Year
Perspective for Cardiac Biomarkers by Geographic Region -
Percentage Breakdown of Dollar Revenues for China, India,
and Rest of Asia-Pacific Markets for Years 2009, 2016, and 2022
(includes corresponding Graph/Chart)..............III-63 Cardiac
Biomarkers Testing By Location of Testing III-64 Table 70:
Asia-Pacific Recent Past, Current and Future Analysis for Cardiac
Biomarkers by Location of Testing - Laboratory Testing &
Point-of-Care Testing Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for Years 2015 through 2022
(includes corresponding Graph/Chart)..............III-64
Table 71: Asia-Pacific Historic Review Analysis for Cardiac
Biomarkers by Location of Testing - Laboratory Testing &
Point-of-Care Testing Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for Years 2009 through 2014
(includes corresponding Graph/Chart) III-65
Table 72: Asia-Pacific 14-Year
Perspective for Cardiac Biomarkers by Location of Testing -
Percentage Breakdown of Dollar Revenues for Laboratory Testing
& Point-of-Care Testing Markets for Years 2009, 2016, and 2022
(includes corresponding Graph/Chart)..............III-66
5a. CHINA.............. III-67
A.Market Analysis.............. III-67 Current and Future
Analysis..............III-67 Product Introductions & Approval
III-67 B.Market Analytics..............III-68 Table 73: Chinese
Recent Past, Current and Future Analysis for Cardiac Biomarkers by
Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2015 through 2022 (includes corresponding
Graph/Chart) III-68
Table 74: Chinese Historic Review Analysis for Cardiac Biomarkers
by Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-69
Table 75: Chinese 14-Year Perspective for Cardiac Biomarkers by
Location of Testing - Percentage Breakdown of Dollar Revenues for
Laboratory Testing & Point-of-Care Testing Markets for Years
2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-70
5b. INDIA.............. III-71
Market Analysis.............. III-71 Table 76: Indian Recent Past,
Current and Future Analysis for Cardiac Biomarkers by Location of
Testing - Laboratory Testing & Point-of-Care Testing Markets
Independently Analyzed with Annual Revenue Figures in US$ Thousand
for Years 2015 through 2022 (includes corresponding Graph/Chart)
III-71
Table 77: Indian Historic Review Analysis for Cardiac Biomarkers by
Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-72
Table 78: Indian 14-Year Perspective for Cardiac Biomarkers by
Location of Testing - Percentage Breakdown of Dollar Revenues for
Laboratory Testing & Point-of-Care Testing Markets for Years
2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-73
5c. REST OF ASIA-PACIFIC..............III-74 A.Market
Analysis.............. III-74 Boditech Med Inc. (South Korea) - A Key Player III-74 B.Market
Analytics..............III-75 Table 79: Rest of Asia-Pacific Recent
Past, Current and Future Analysis for Cardiac Biomarkers by
Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2015 through 2022 (includes corresponding
Graph/Chart).............. III-75
Table 80: Rest of Asia-Pacific Historic Review Analysis for Cardiac
Biomarkers by Location of Testing - Laboratory Testing &
Point-of-Care Testing Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for Years 2009 through 2014
(includes corresponding Graph/Chart) III-76
Table 81: Rest of Asia-Pacific
14-Year Perspective for Cardiac Biomarkers by Location of Testing -
Percentage Breakdown of Dollar Revenues for Laboratory Testing
& Point-of-Care Testing Markets for Years 2009, 2016, and 2022
(includes corresponding Graph/Chart) III-77
6. LATIN AMERICA..............
III-78 Market Analysis.............. III-78 Table 82: Latin
American Recent Past, Current and Future Analysis for Cardiac
Biomarkers by Geographic Region - Brazil, and Rest of Latin America Markets
Independently Analyzed with Annual Revenue Figures in US$ Thousand
for Years 2015 through 2022 (includes corresponding Graph/Chart)
III-78
Table 83: Latin American Historic Review Analysis for Cardiac
Biomarkers by Geographic Region - Brazil, and Rest of Latin America Markets
Independently Analyzed with Annual Revenue Figures in US$ Thousand
for Years 2009 through 2014 (includes corresponding Graph/Chart)
III-79
Table 84: Latin American 14-Year Perspective for Cardiac Biomarkers
by Geographic Region - Percentage Breakdown of Dollar Revenues for
Brazil, and Rest of Latin America
Markets for Years 2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-80 Cardiac Biomarkers Testing By
Location of Testing III-81 Table 85: Latin American Recent Past,
Current and Future Analysis for Cardiac Biomarkers by Location of
Testing - Laboratory Testing & Point-of-Care Testing Markets
Independently Analyzed with Annual Revenue Figures in US$ Thousand
for Years 2015 through 2022 (includes corresponding
Graph/Chart)..............III-81
Table 86: Latin American Historic Review Analysis for Cardiac
Biomarkers by Location of Testing - Laboratory Testing &
Point-of-Care Testing Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for Years 2009 through 2014
(includes corresponding Graph/Chart).............. III-82
Table 87: Latin American 14-Year Perspective for Cardiac Biomarkers
by Location of Testing - Percentage Breakdown of Dollar Revenues
for Laboratory Testing & Point-of-Care Testing Markets for
Years 2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-83
6a. BRAZIL.............. III-84
Market Analysis.............. III-84 Table 88: Brazilian Recent
Past, Current and Future Analysis for Cardiac Biomarkers by
Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2015 through 2022 (includes corresponding
Graph/Chart) III-84
Table 89: Brazilian Historic Review Analysis for Cardiac Biomarkers
by Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2009 through 2014 (includes corresponding
Graph/Chart) III-85
Table 90: Brazilian 14-Year Perspective for Cardiac Biomarkers by
Location of Testing - Percentage Breakdown of Dollar Revenues for
Laboratory Testing & Point-of-Care Testing Markets for Years
2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-86
6b. REST OF LATIN-AMERICA..............III-87 Market
Analysis.............. III-87 Table 91: Rest of Latin-America
Recent Past, Current and Future Analysis for Cardiac Biomarkers by
Location of Testing - Laboratory Testing & Point-of-Care
Testing Markets Independently Analyzed with Annual Revenue Figures
in US$ Thousand for Years 2015 through 2022 (includes corresponding
Graph/Chart).............. III-87
Table 92: Rest of Latin-America Historic Review Analysis for
Cardiac Biomarkers by Location of Testing - Laboratory Testing
& Point-of-Care Testing Markets Independently Analyzed with
Annual Revenue Figures in US$ Thousand for Years 2009 through 2014
(includes corresponding Graph/Chart) III-88
Table 93: Rest of Latin-America
14-Year Perspective for Cardiac Biomarkers by Location of Testing -
Percentage Breakdown of Dollar Revenues for Laboratory Testing
& Point-of-Care Testing Markets for Years 2009, 2016, and 2022
(includes corresponding Graph/Chart) III-89
7. REST OF WORLD.............. III-90 Market Analysis..............
III-90 Table 94: Rest of World Recent Past, Current and Future
Analysis for Cardiac Biomarkers by Location of Testing - Laboratory
Testing & Point-of-Care Testing Markets Independently Analyzed
with Annual Revenue Figures in US$ Thousand for Years 2015 through
2022 (includes corresponding Graph/Chart).............. III-90
Table 95: Rest of World Historic Review Analysis for Cardiac
Biomarkers by Location of Testing - Laboratory Testing &
Point-of-Care Testing Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for Years 2009 through 2014
(includes corresponding Graph/Chart) III-91
Table 96: Rest of World 14-Year Perspective for Cardiac Biomarkers
by Location of Testing - Percentage Breakdown of Dollar Revenues
for Laboratory Testing & Point-of-Care Testing Markets for
Years 2009, 2016, and 2022 (includes corresponding
Graph/Chart)..............III-92
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 44 (including Divisions/Subsidiaries -
50)
The United States (26)
Canada (3) Europe (14) - France (1) - Germany (1) - The United Kingdom (3) - Rest of Europe (9) Asia-Pacific (Excluding Japan) (7)
Download the full report:
https://www.reportbuyer.com/product/3846692/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that
provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/global-cardiac-biomarker-industry-300275999.html
SOURCE ReportBuyer